BioLargo (BLGO) investor relations material

Strategic partnerships and commercialization progress

• Entered a strategic relationship with Aquatech to jointly serve customers, combining technologies and resources for PFAS solutions, with active global engagement and industry recognition underway.

• The partnership is not a legal entity but a collaborative business relationship, aiming to address shifting PFAS market needs and regulatory pressures.

• The pipeline for AEC PFAS technology exceeds $200 million, with projects ranging from $5 million to over $100 million, now more credible due to Aquatech's involvement.

• Active contract proposals are being delivered globally, with a focus on scaling manufacturing and integrating engineering resources.

• The relationship with Aquatech is in the active deployment planning phase, with ongoing technical collaboration and no set timeline for first deployments.

Regulatory and market dynamics

• Regulatory events and funding, such as those under the Clean Water Act, have accelerated PFAS solution adoption, with OpEx now a key concern for municipal clients.

• Customers are seeking future-proof, cost-effective solutions due to tightening regulations and downstream costs associated with traditional carbon-based systems.

• New regulatory enforcement and settlements are expanding the scope of opportunities for PFAS solutions.

Subsidiary and product updates

• Clyra is preparing for a major commercial launch, with a second distributor signed and a focus on securing a significant global partner; FDA packaging submission is pending, targeting a fall launch.

• The ViaClyr product is progressing in the European market through Al-Hikma FZCO, with regulatory filings and clinical work ongoing.

• Dental applications for Clyra are on hold until more bandwidth and revenue success are achieved.

• ONM Environmental is repositioning after a license dispute, with litigation ongoing and plans to leverage existing assets for future growth.